Literature DB >> 21323970

Should we consider cancer/testis antigens NY-ESO-1, MAGE-A4 and MAGE-A1 as potential targets for immunotherapy in vulvar squamous cell carcinoma?

Jacek J Sznurkowski, Anton Zawrocki, Joanna Karczewska, Janusz Emerich, Wojciech Biernat.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21323970     DOI： 10.1111/j.1365-2559.2011.03772.x

Source DB:  PubMed          Journal:  Histopathology        ISSN： 0309-0167            Impact factor:   5.087


× No keyword cloud information.
  2 in total

Review 1.  Trial watch: Dendritic cell-based anticancer therapy.

Authors:  Norma Bloy; Jonathan Pol; Fernando Aranda; Alexander Eggermont; Isabelle Cremer; Wolf Hervé Fridman; Jitka Fučíková; Jérôme Galon; Eric Tartour; Radek Spisek; Madhav V Dhodapkar; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2014-12-21       Impact factor: 8.110

2.  High numbers of activated helper T cells are associated with better clinical outcome in early stage vulvar cancer, irrespective of HPV or p53 status.

Authors:  Kim E Kortekaas; Saskia J Santegoets; Ziena Abdulrahman; Vanessa J van Ham; Marij van der Tol; Ilina Ehsan; Helena C van Doorn; Tjalling Bosse; Mariëtte I E van Poelgeest; Sjoerd H van der Burg
Journal:  J Immunother Cancer       Date:  2019-09-03       Impact factor: 13.751
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.